Informed Prostate Cancer Patient Support

Dr. Laurence Klotz, MD, 2022 Recipient of Chodak Award - YouTube

Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution - Casadó‐Llombart - - The Prostate - Wiley Online Library

Simple Biomarker Test Could Help Guide Prostate Biopsy Decisions

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence | Cancer Discovery | American Association for Cancer Research

Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms | Prostate Cancer and Prostatic Diseases

Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study - Miura - - The Prostate - Wiley Online Library

Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only | Prostate Cancer and Prostatic Diseases

(PDF) Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) | Request PDF

What to Say to Your Partner Who Has Prostate Cancer webmd.com What to Say to Your Partner Who Has Prostate Cancer 7-9 minutes When you find out that your partner has prostate cancer , both of you probably have a lot of questions about what comes next. There will be plenty you need to talk about. But what do you say -- and what shouldn’t you say -- as you face the disease together? Before you choose your words, focus on the “together” part of this. Your partner will benefit greatly by you being at his side. Go to his appointments with him and be supportive. “If the man has a partner, I always encourage that partner to be there,” says urologist Jesse Mills, MD, director of the Men’s Clinic at UCLA in Los Angeles. “This is a disease that couples suffer together.” Urologist Clayton Lau, MD, agrees. “Say to your partner that you want to be involved, go to appointments, ask questions,” says L

The Future of Metastatic Prostate Cancer Management | MedPage Today

Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms | Prostate Cancer and Prostatic Diseases

Statins and prostate cancer—hype or hope? The epidemiological perspective | Prostate Cancer and Prostatic Diseases

Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case | npj Precision Oncology

The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis | Prostate Cancer and Prostatic Diseases

Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States | Prostate Cancer and Prostatic Diseases

A New Standard of Care After Prostate Surgery — Cancer ABCs

Clovis Oncology, Inc. - Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

Why Clovis Oncology Stock Is Blasting Off Today | The Motley Fool

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer | RadioGraphics

Expert Report on latest data in the management of metastatic prostate cancer from ASCO 2022 - YouTube

(65261) Inoreader - GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis

A New Standard of Care After Prostate Surgery — Cancer ABCs cancerabcs.org A New Standard of Care After Prostate Surgery — Cancer ABCs 4 minutes According to an international study led by Alan Pollack, M.D., Ph.D., chair and professor of radiation oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and published in The Lancet, adding short-term hormone therapy (ADT) and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose PSA levels are rising post-prostatectomy.  According to Dr. Pollack, a rising PSA following prostatectomy for prostate cancer is a sign

Pan-cancer whole genome comparison of primary and metastatic solid tumors | bioRxiv

'Substandard' Control Arms in Clinical Trials– Practice Found Common in Prostate Cancer Studies — Cancer ABCs

MRI-Guided HIFU Effective in Intermediate-Risk Prostate Cancer | MedPage Today

Active Treatment or Observation for Localized Prostate Cancer?

A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients - ScienceDirect

Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study - International Journal of Radiation Oncology, Biology, Physics

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

Xtandi During AS Reduced Progression Risk in Early Prostate Cancer | MedPage Today

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study - The Lancet Oncology thelancet.com MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study Search for articles by this author 8-10 minutes Summary Background Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer

Mechanism leading to drug resistance in prostate cancer: Consecutive molecular modifications of the androgen receptor can contribute to drug resistance, which can be blocked with an ACK1 inhibitor -- ScienceDaily sciencedaily.com Mechanism leading to drug resistance in prostate cancer: Consecutive molecular modifications of the androgen receptor can contribute to drug resistance, which can be blocked with an ACK1 inhibitor 4-6 minutes Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy. However, despite the benefits of this therapy, almost all patients will eventually develop drug resistance and recurrent disease. In a new article published in Science Translational Medicine , Moffitt Cancer Center researchers reveal a mechanism by which prostate cancer cells be

Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review - ScienceDirect : Prostate-specific membrane antigen is a transmembrane protein found predominately on prostate epithelium and is expressed at high levels in prostate c…

Radium-223 for Metastatic Castrate-Resistant Prostate Cancer - ScienceDirect

High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects In recent years, a new treatment strategy known as focal therapy (partial gland ablation) has emerged for prostate cancer considered to be "intermediate risk" -- mostly, small tumors confined to one area of the prostate. At Memorial Sloan Kettering Cancer Center (MSK), researchers have been working closely with an advanced focal therapy approach known as high-intensity focused ultrasound (HIFU), guided by magnetic resonance imaging (MRI). Now a landmark clinical trial has demonstrated this less-invasive method works well for many patients. The phase 2 trial, led by MSK urologic cancer surgeon Behfar Ehdaie, looked at a particular type of HIFU treatment, also called MR-guided focused ultrasound (MRgFUS), in men with intermediate-risk cancer. The novel approach effectively controlled the disease in patients and greatly reduced adverse side effects of tr

Family History Linked to Elevated Risks of Prostate Cancer-Specific Death | MedPage Today

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy | Scientific Reports : We aimed to determine the survival and staging benefit of limited pelvic lymph node dissection (PLND) during radical prostatectomy (RP) in high-risk prostate cancer (PC) patients treated with neoadjuvant chemohormonal therapy. We retrospectively analyzed 516 patients with high-risk localized PC (< cT4N0M0) who received neoadjuvant androgen-deprivation therapy plus estramustine phosphate followed by RP between January 2010 and March 2020. Since we stopped limited PLND for such patients in October 2015, we compared the surgical outcomes and biochemical recurrence-free survival (BCR-FS) between the limited-PLND group (before October 2015, n = 283) and the non-PLND group (after November 2015, n = 233). The rate of node metastases in the limited-PLND group were 0.8% (2/283). Operation time was significantly long

Sweet relief: the treechangers growing ‘miracle berries’ to help cancer patients taste again | Queensland | The Guardian theguardian.com Sweet relief: the treechangers growing ‘miracle berries’ to help cancer patients taste again D on Anderson describes himself as “a sceptic” but, four years ago, when he lost his sense of taste while undergoing radium therapy for prostate cancer, Anderson turned to an unorthodox treatment for relief. “Yeah, I was doubtful,” the retired fisherman and boat skipper from Port Douglas says. “But I was also pretty fed up with everything tasting totally bland, so I thought I’d give it a go. I had nothing to lose.” What Anderson tried was the fruit of Synsepalum dulcificum , known colloquially as “miracle fruit” or “miracle berry” – not for its health qualities but its impact on people’s tastebuds. The bush, which originates in central and west Africa, made its way to sub-tropical Queensland in the late 1970s

Could Milk Raise a Man's Odds for Prostate Cancer?

Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study | Prostate Cancer and Prostatic Diseases

Systematic Development of Solid Lipid Nanoparticles of Abiraterone Acetate with Improved Oral Bioavailability and Anticancer Activity for Prostate Carcinoma Treatment - Docwire News

New Advances Transform Treatment of Prostate Cancer

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups - Stenzl - - The Prostate - Wiley Online Library Abstract Background Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival versus ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in ARCHES (NCT02677896). While health-related quality of life (HRQoL) was generally maintained in the intent-to-treat population, we further analyzed patient-reported outcomes (PROs) in defined subgroups. Methods ARCHES was a randomized, double-blind, placebo-controlled, phase 3 study. Patients with mHSPC received enzalutamide (160 mg/day) p

The Long-Term Effect of Intensity Modulated Radiation Therapy for Prostate Cancer on Testosterone Levels - PubMed

Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy | Prostate Cancer and Prostatic Diseases

First-Line Options in Metastatic Castration-Resistant Prostate Cancer | MedPage Today

New Therapy for Aggressive Prostate Cancer Improves Survival | National Cancer Center, Inc. nationalcancercenter.org New Therapy for Aggressive Prostate Cancer Improves Survival | National Cancer Center, Inc. By NantionalCC 2-3 minutes There is some very good news on the prostate cancer front. According to an article in the New York Times on June 25, 2021, a new therapy for aggressive prostate cancer has been developed that will increase survival rates. It relies on a radioactive molecule to target a protein found on the surface of prostate cancer cells. This new targeted therapy drives radiation straight to the cancer itself, and the place where the cancer “lives,” without damaging surrounding tissue.  It may have applications for the treatment of other cancers.  “This represents an exciting and significant advancement in the treatment of prostate cancer,”

The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High Risk Prostate Cancer: A Validation Study from NRG/RTOG 0521 - ScienceDirect

The Long-Term Effect of Intensity Modulated Radiation Therapy for Prostate Cancer on Testosterone Levels - Docwire News docwirenews.com The Long-Term Effect of Intensity Modulated Radiation Therapy for Prostate Cancer on Testosterone Levels 3 minutes This article was originally published here Adv Radiat Oncol. 2021 Nov 17;7(3):100851. doi: 10.1016/j.adro.2021.100851. eCollection 2022 May-Jun. ABSTRACT PURPOSE: Concern about a long-term effect of the delivery of intensity modulated radiation therapy (IMRT) for prostate cancer on serum testosterone levels remains unelucidated. We evaluated how IMRT for localized prostate cancer affects serum testosterone levels during a follow-up period of up to 10 years. METHODS AND MATERIALS: We retrospectively evaluated data from 182 patients with localized prostate cancer who underwent definitive IMRT alone between 2007 and 2014. Serum total testoste

Genetics and genomics of prostate cancer and therapeutic implications - Antonarakis - 2022 - The Prostate - Wiley Online Library onlinelibrary.wiley.com Genetics and genomics of prostate cancer and therapeutic implications Emmanuel S. Antonarakis MD 5-6 minutes First published: 03 June 2022 Continuing Medical Education: Please Click Here to complete an accredited learning activity for this article and receive 1.0 AMA PRA Category 1 Credit™. Over the last 5 years, there has been an exponential increase in our understanding and characterization of the germline and somatic molecular landscapes of prostate cancer. This has led to a clearer appreciation of the genetic, genomic, transcriptomic, and (phospho)proteomic drivers of localized and advanced prostate cancers, as well as the evolutionary

Germline genetics of prostate cancer - Khan - 2022 - The Prostate - Wiley Online Library onlinelibrary.wiley.com Germline genetics of prostate cancer Hiba M. Khan 36-46 minutes 1 INTRODUCTION It has been well established that prostate cancer has a strong genetic association. The discovery of populations with higher prevalence of single high penetrance risk factors such as BRCA2 in specific subgroups such as men with metastatic disease, paired with the increased availability and decreased cost of next-generation sequencing have led to the expanded recommendations for germline genetic testing in patients with prostate cancer. These new technologies have led to the discovery of more germline genetic factors implicated in prostate cancer and are now accompanied by new US Food and Drug Administration (FDA)-approved treatment options in the advan